Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the top penny stocks to buy in investors’ stock portfolio.
On May 8, Stifel reiterated a Hold rating on Aclaris Therapeutics Inc. (NASDAQ:ACRS) and increased the price target to $4 from $3
The price target hike underscores the research firm’s optimism about the company’s multi-targeting approaches and its novel immunology biology. The company has made significant progress in developing best-in-class compounds to address various immunological diseases. For starters, it has delivered positive results in the Phase 1a SAD/MAD trial of bispecific antibody ATI-052.
Aclaris is also anticipating top-line results in ongoing Phase 1b proof-of-concept trials or ATI-052. The candidate therapy continues to show potential in the treatment of various atopic immunologic and respiratory diseases. The company is also pursuing the Lichen Planus Development Strategy for ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3.